Effect Of YH-16 On Blood Pressure, Coagulation And Fibrinolytic Function Of Malignant Tumor Treated With Radiotherapy

The angiogenesis inhibitors have been becoming a new method for treatment of tumor and they show the superiority over traditional chemotherapy in some ways and can enhance the effectiveness of radiotherapy. However, there are several adverse reactions to angiogenesis inhibitors during some clinical trials, including hypertension, thrombosis and hemorrhage, some of which such as atheroembolism, DIC (disseminated intravascular coagulation) and acute gastrointestinal hemorrhage limit their clinical use. YH-16 is a new type of angiogenesis inhibitor with broad-spectrum anti-angiogenesis effect, which is researched and developed by chinese. By analysing the changes of related data of malignant tumor treated with YH-16 united 3DCRT, we discuss the possible adverse reactions and provide evidence of utilizing YH-16.Objective To observe the changes of blood pressure, coagulation and fibrinolytic function of malignant tumor treated with YH-16 united with 3DCRT, and discuss the possibility of hypertension, hemorrhage and thromboembolism caused by YH-16.Materials and Methods A total of 30 malignancy patients with histopathological or cytologic evidence between April 2008 and August 2009 at my department were divided into two groups at random. The control group (15patients) received 3DCRT and the YH-16 group (15patients) was treated with YH-16 15mg, ivdrip, dl～14 when receving 3DCRT. Gross tumor volume was determined by outlining the margins of the visible primary or metastatic tumor and any enlarged regional lymph nodes. The treatment was administered by a high energy, linear accelerator(6 or 10 MV photons) and 3DCRT was delivered using a standard irradiation (200cGy/day for five days/week). The total dose was 60～70Gy. The serum PT, APTT, Fib, D-dimer were measured with automatic coagulometer in d 0,3,7,14 when YH-16 was used. Blood pressure was measured twice in the mornting and evening every other day during the treatment, means of which were taken for use.Results PT and FIb of the YH-16 group in d7,14 but not APTT, TT, D-dimer, blood pressure, significantly changed in relation to those of the control group.Conclusion YH-16 impacts the coagulation function of malignant tumor patients. Angiogenesis is one of the foundation of growth, infiltration and metastasis of tumor. Tumor angiogenesis inhibitors which can inhibit or destroy angiogenesis of tumor have been becoming an important method of treatment of malignancy in addition to surgery, radiotherapy and chemoterapy. We summarized recent researches about the development of tumor angiogenesis inhibitors in this review.